EUCTR2004-004917-41-IT进行中（未招募）不适用
A prospective, randomized, double-blind, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil MMF in inducing response and maintaining remission in subjects with lupus nephritis
ASPREVA PHARMACEUTICALS CORPORATIO0 个研究点目标入组 358 人开始时间: 2007年2月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 358
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A prospective, randomized, double-blind, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in inducing response and maintaining remission in subjects with lupus nephritis. - Aspreva Lupus Management Study (ALMS)EUCTR2004-004917-41-PTAspreva Pharmaceuticals Corporation as part of the Roche-Aspreva Collaboration Agreement358
进行中（未招募）
不适用
A prospective, randomized, double-blind, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in inducing response and maintaining remission in subjects with lupus nephritis. - Aspreva Lupus Management Study (ALMS)upus NephritisMedDRA version: 4.1Level: LowClassification code 10025140EUCTR2004-004917-41-HUAspreva Pharmaceuticals Corporation as part of the Roche-Aspreva Collaboration Agreement358
已完成
3 期
The Influence of Anaesthetic Depth on Patient Outcome after Major SurgeryACTRN12612000632897Assoc Professor Dr Timothy Short6,649
进行中（未招募）
不适用
linagliptin in combination with metformin in treatment naive patients with type 2 diabetes mellitus and insufficient glycaemic controlType 2 diabetes MellitusMedDRA version: 14.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-002276-16-DEBoehringer Ingelheim Pharma GmbH & Co. KG1,360
进行中（未招募）
1 期
linagliptin in combination with metformin in treatment naive patients with type 2 diabetes mellitus and insufficient glycaemic control.Type 2 diabetes MellitusMedDRA version: 14.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-002276-16-ESBoehringer Ingelheim España, S.A.1,360